Results 21 to 30 of about 350,390 (302)

Reuse of drugs in the treatment of COVID-19

Research, Society and Development, 2022
After an outbreak of atypical pneumonia in the city of Wuhan, China, there were epidemiological alerts due to the unknown factor. On January 7, 2020, Chinese scientists isolated a strain of coronavirus, in which the etiologic agent was identified. It quickly spread around the world and, therefore, it was declared a pandemic on March 11, 2020. From then
Alessandra Isabô Neri, Lílian Carla Carneiro, Cristiene Costa Carneiro, Aroldo Vieira de Moraes Filho, Lee Chen-Chen   +4 more
openaire   +2 more sources

Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates

Molecules, 2022
In December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) was first identified in the province of Wuhan, China.
Liliana Rodrigues, Renata Bento Cunha, Tatiana Vassilevskaia, Miguel Viveiros, Celso Cunha   +4 more
doaj   +1 more source

Drug interactions in COVID-19 treatment. Systematic review [PDF]

Farmacja Polska, 2022
The COVID-19 pandemic has driven the experimental, off-label treatments with co-administration of supportive therapies for many patients with severe infections and coexisting chronic conditions. This situation has inevitably led to polypharmacy, which is
Arkadiusz Adamiszak, Tomasz Torliński, Edmund Grześkowiak, Alicja Bartkowska-Śniatkowska, Agnieszka Bienert   +4 more
doaj   +1 more source

Knowledge-Graph-Based Drug Repositioning against COVID-19 by Graph Convolutional Network with Attention Mechanism

Future Internet, 2021
The current global crisis caused by COVID-19 almost halted normal life in most parts of the world. Due to the long development cycle for new drugs, drug repositioning becomes an effective method of screening drugs for COVID-19. To find suitable drugs for
Mingxuan Che, Kui Yao, Chao Che, Zhangwei Cao, Fanchen Kong   +4 more
doaj   +1 more source

Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern. The fragile balance between infections and autoimmunity [PDF]

, 2020
On 7 January 2020, researchers isolated and sequenced in China from patients with severe pneumonitis a novel coronavirus, then called SARS-CoV-2, which rapidly spread worldwide, becoming a global health emergency.
Diamanti, A. P., Lagana, B., Pioli, C., Rosado, M. M., Sesti, G.   +4 more
core   +2 more sources

CSF3 Is a Potential Drug Target for the Treatment of COVID-19 [PDF]

Frontiers in Physiology, 2021
Coronavirus Disease 2019 (COVID-19) is an acute respiratory infectious disease that appeared at the end of 2019. As of July 2020, the cumulative number of infections and deaths have exceeded 15 million and 630,000, respectively. And new cases are increasing.
Chao Fang, Chao Fang, Jie Mei, Huixiang Tian, Yu-Ligh Liou, Dingchao Rong, Wei Zhang, Qianjin Liao, Nayiyuan Wu, Nayiyuan Wu   +9 more
openaire   +3 more sources

Secondary Publication: COVID-19 Pandemic: Drug Development and Treatment

Tokyo Women's Medical University Journal, 2021
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019. It has been rapidly spreading worldwide ever since.
Fujiko Tsukahara, Yoshiro Maru
doaj   +1 more source

Repurposing Existing Drugs for the Treatment of COVID-19

Annals of the American Thoracic Society, 2020
Abstract The rapid global spread and significant mortality associated with the coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection has spurred an urgent race to find effective treatments.
Hugo Farne, Kartik Kumar, Andrew I. Ritchie, Lydia J. Finney, Sebastian L. Johnston, Aran Singanayagam   +5 more
openaire   +3 more sources

COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions [PDF]

British Journal of Clinical Pharmacology, 2020
In a recent issue of Br J Clin Pharmacol Smith et al1 published an outstanding commentary titled ‘Dosing will be a key success factor in repurposing antivirals for Covid-19’. They highlighted that the success in our repurposing efforts will be dependent on ‘getting the dose right’ for drugs which have been developed for different indications and ...
Back, David, Marzolini, Catia, Hodge, Catherine, Marra, Fiona, Boyle, Alison, Gibbons, Sara, Burger, David, Khoo, Saye   +7 more
openaire   +8 more sources

Investigational antiviral drugs for the treatment of COVID-19 patients [PDF]

Archives of Virology, 2022
In the current pandemic of coronavirus disease 2019 (COVID-19), antiviral drugs are at the center of attention because of their critical role against severe acute respiratory disease syndrome coronavirus 2 (SARS-CoV-2). In addition to designing new antivirals against SARS-COV-2, a drug repurposing strategy is a practical approach for treating COVID-19.
Samineh Beheshtirouy, Elnaz Khani, Sajad Khiali, Taher Entezari-Maleki   +3 more
openaire   +2 more sources